热门出版物 - 学术资源搜索

h5 指数:202
h5 中位数:329

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2017-2021 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#2 Oncology
#8 Health & Medical Sciences

标题/作者	引用次数	年份
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China W Liang, W Guan, R Chen, W Wang, J Li, K Xu, C Li, Q Ai, W Lu, H Liang, ... The Lancet Oncology 21 (3), 335-337	4054	2020
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ... The Lancet Oncology 18 (9), 1182-1191	1699	2017
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952	1343	2018
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial P Sharma, M Retz, A Siefker-Radtke, A Baron, A Necchi, J Bedke, ... The Lancet Oncology 18 (3), 312-322	1321	2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ... The Lancet Oncology 18 (3), e143-e152	1298	2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The Lancet Oncology 18 (9), 1274-1284	1154	2017
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The Lancet Oncology 20 (1), 31-42	1078	2019
International incidence of childhood cancer, 2001–10: a population-based registry study E Steliarova-Foucher, M Colombet, LAG Ries, F Moreno, A Dolya, F Bray, ... The Lancet Oncology 18 (6), 719-731	1048	2017
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study C Maringe, J Spicer, M Morris, A Purushotham, E Nolte, R Sullivan, ... The Lancet Oncology 21 (8), 1023-1034	965	2020
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ... The Lancet Oncology 19 (1), 40-50	958	2018
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ... The Lancet Oncology 20 (2), 282-296	910	2019
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ... The Lancet Oncology 19 (11), 1480-1492	900	2018
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study AV Balar, D Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ... The Lancet Oncology 18 (11), 1483-1492	897	2017
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The Lancet Oncology 18 (1), 75-87	885	2017
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ... The Lancet Oncology 18 (1), 31-41	797	2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, F Tsuji, R Linke, ... The Lancet Oncology 18 (11), 1454-1466	752	2017
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas M Weller, M van den Bent, JC Tonn, R Stupp, M Preusser, ... The Lancet Oncology 18 (6), e315-e329	748	2017
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial N Shaverdian, AE Lisberg, K Bornazyan, D Veruttipong, JW Goldman, ... The Lancet Oncology 18 (7), 895-903	738	2017
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial H West, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ... The Lancet Oncology 20 (7), 924-937	720	2019
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ... The Lancet Oncology 18 (11), 1493-1501	707	2017

1 - 20

计算机程序会自动估算并确定日期和引用次数。